What the study found
Oral nirmatrelvir-ritonavir did not reduce hospitalization or death among vaccinated higher-risk people with SARS-CoV-2 infection.
Why the authors say this matters
The abstract does not describe additional implications beyond reporting this result.
What the researchers tested
The researchers reported findings from two open-label trials of nirmatrelvir-ritonavir in vaccinated higher-risk outpatients with SARS-CoV-2 infection. The trials were PANORAMIC and CanTreatCOVID.
What worked and what didn't
The treatment did not reduce the incidence of hospitalization or death in the participants studied. The abstract does not report any other benefits or harms.
What to keep in mind
The summary available here is limited to the abstract. The abstract does not provide further details about trial methods, outcomes beyond hospitalization or death, or limitations.
Key points
- Nirmatrelvir-ritonavir did not reduce hospitalization or death in the studied group.
- The participants were vaccinated higher-risk outpatients with SARS-CoV-2 infection.
- The evidence came from two open-label trials: PANORAMIC and CanTreatCOVID.
- The abstract does not report additional benefits, harms, or limitations.
Disclosure
- Research title:
- Nirmatrelvir-ritonavir did not reduce hospitalization or death
- Authors:
- Christopher C. Butler, Andrew Pinto, Victoria Harris, Jane Holmes, Najib M. Rahman, Lucy Cureton, Gail Hayward, Duncan B. Richards, David M. Lowe, Joseph F. Standing, Judith Breuer, Kerenza Hood, May Ee Png, Stavros Petrou, Jienchi Dorward, Mahendra G. Patel, Nicholas P.B. Thomas, Philip Evans, Nigel D. Hart, B Jani, Banafshe Hosseini, Srinivas Murthy, Kerry McBrien, Amanda Condon, Emily G. McDonald, Peter Daley, Michelle Greiver, Bruno R. da Costa, Peter Selby, Peter Jüni, T Lee, Haolun Shi, Michelle A. Detry, Christina Saunders, Mark Fitzgerald, Nicholas Berry, Benjamin R. Saville, Saye Khoo, Jonathan S. Nguyen-Van-Tam, F.D. Richard Hobbs, Ly-Mee Yu, Paul Little
- Institutions:
- 3M (United States), 3M (United States), 3M (United States), 3M (United States), 3M (United States), Berry & Associates (United States), Berry & Associates (United States), Berry & Associates (United States), Berry & Associates (United States), Berry & Associates (United States), Cardiff University, Centre for the AIDS Programme of Research in South Africa, Health Solutions (Sweden), Health Solutions (Sweden), Institute of Infection and Immunity, Institute of Infection and Immunity, McGill University, McGill University, McGill University Health Centre, McGill University Health Centre, Memorial University of Newfoundland, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Research, NIHR Southampton Biomedical Research Centre, North York General Hospital, Nuffield Orthopaedic Centre, Orion Corporation (United Kingdom), Queen's University Belfast, Royal College of General Practitioners, Science Oxford, Simon Fraser University, St Michael's Hospital, St Michael's Hospital, St. Michael's Hospital, University College London, University College London, University College London, University of British Columbia, University of Calgary, University of Cambridge, University of Exeter, University of Glasgow, University of Liverpool, University of Manitoba, University of Nottingham, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Oxford, University of Southampton, University of Toronto, University of Toronto, University of Toronto, University of Toronto, University of Toronto, University of Toronto, Vanderbilt University
- Publication date:
- 2026-04-22
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.


